(NASDAQ: BDTX) Black Diamond Therapeutics's forecast annual revenue growth rate of -47.1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.97%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.99%.
Black Diamond Therapeutics's revenue in 2025 is $70,000,000.On average, 3 Wall Street analysts forecast BDTX's revenue for 2025 to be $3,980,384,450, with the lowest BDTX revenue forecast at $3,980,384,450, and the highest BDTX revenue forecast at $3,980,384,450. On average, 1 Wall Street analysts forecast BDTX's revenue for 2027 to be $1,132,703,689, with the lowest BDTX revenue forecast at $1,132,703,689, and the highest BDTX revenue forecast at $1,132,703,689.
In 2028, BDTX is forecast to generate $2,288,721,059 in revenue, with the lowest revenue forecast at $623,783,106 and the highest revenue forecast at $3,953,659,012.